Some Observations on the Coagulation Defect During Treatment with the Anticoagulant “Sintrom”

Conclusions

1. The decrease of activity of prothrombin, occuring during administration of “Sintrom”, becomes only manifest when the activity of “factor VII” has fallen to less than half its normal value.

2. The behaviour of the thrombin time is the manifestation of an important difference between the coagulation defect in hepatitis and that on administration of Sintrom.

 

• References

• 1 Biggs R, Douglas A. S. The measurement of prothrombin in plasma. J. clin. Pathol 1953; 6: 15
• 2 Douglas A. S. The coagulation defect caused by tromexan therapy. Clin. Science 1955; 14: 601
• 3 Lasch H. G, Roka L. Über den Bildungsmechanismus der Gerinnungsfaktoren Prothrombin und VII. Klin. Wschr 1954; 32: 460
• 4 Macfarlane R. G, Biggs R. A thrombin generation test. J. Clin. Pathol 1953; 6: 3
• 5 Marx R. Über den Wert der Bestimmungen von Blutgerinnungsfaktoren für die Beurteilung von Leberkrankheiten. Das Ärztl. Laboratorium. Heft 1956; 8: 309-319
• 6 Schultze H. E, Schwick G. Laboratoriumsblätter Nr. 2 1953
• 7 Vermeulen H. J, Bokkel Huinink S. A, ten K. SRadhakishun. Klinische ervaringen met het anticoagulans Sintrom. Ned. T. v. Geneesk 1957; 101: 1218